This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
clinical signs | 1569 |
mg kg | 868 |
clinical trials | 804 |
acute respiratory | 644 |
coronavirus disease | 596 |
novel coronavirus | 570 |
guinea pigs | 452 |
respiratory syndrome | 422 |
united states | 408 |
clinical trial | 399 |
respiratory distress | 387 |
differential diagnosis | 380 |
may also | 369 |
severe covid | 363 |
case report | 362 |
severe acute | 360 |
en el | 358 |
health care | 344 |
intensive care | 340 |
critically ill | 340 |
liver disease | 331 |
may occur | 330 |
clinical characteristics | 321 |
risk factors | 313 |
pacientes con | 298 |
weight loss | 294 |
outcome measures | 293 |
main outcome | 283 |
stem cells | 276 |
systematic review | 273 |
public health | 257 |
please specify | 254 |
distress syndrome | 254 |
clinical practice | 254 |
abstract type | 254 |
syndrome coronavirus | 245 |
respiratory tract | 240 |
side effects | 238 |
en pacientes | 238 |
clinical features | 228 |
retrospective study | 226 |
small intestine | 223 |
blood pressure | 223 |
se recomienda | 222 |
lymph nodes | 216 |
gastrointestinal tract | 214 |
los pacientes | 212 |
ill patients | 211 |
mechanical ventilation | 211 |
clinical pharmacy | 206 |
bone marrow | 203 |
nervous system | 203 |
cohort study | 201 |
clinical research | 200 |
learning objectives | 195 |
abdominal pain | 193 |
hospitalized patients | 192 |
physical examination | 191 |
chronic hepatitis | 185 |
con covid | 185 |
infectious diseases | 185 |
care unit | 182 |
animal models | 180 |
may result | 180 |
one study | 180 |
mesenchymal stem | 180 |
imaging findings | 179 |
small intestinal | 178 |
immune response | 175 |
patient care | 174 |
virus infection | 174 |
kg iv | 173 |
lopinavir ritonavir | 173 |
computed tomography | 172 |
magnetic resonance | 172 |
mean age | 170 |
clinical course | 170 |
guinea pig | 170 |
blood flow | 169 |
methods materials | 168 |
clinical findings | 168 |
soft tissue | 165 |
foreign bodies | 161 |
epithelial cells | 160 |
may cause | 157 |
stem cell | 157 |
convalescent plasma | 155 |
adverse effects | 152 |
heart failure | 152 |
trauma patients | 152 |
also may | 152 |
renal failure | 151 |
abstract background | 151 |
research abstract | 151 |
tissue engineering | 150 |
severe cases | 150 |
clinical studies | 149 |
heart rate | 149 |
central nervous | 148 |
definitive diagnosis | 147 |
ml kg | 146 |
immune system | 146 |
years old | 145 |
inflammatory response | 145 |
oral health | 144 |
cytokine storm | 143 |
mortality rate | 142 |
mr imaging | 142 |
increased risk | 140 |
affected animals | 139 |
supportive care | 139 |
patients treated | 138 |
respiratory failure | 137 |
en los | 137 |
foreign body | 135 |
clinical improvement | 135 |
rights reserved | 135 |
important role | 134 |
cord uid | 134 |
doc id | 134 |
multiple sclerosis | 134 |
clinical pharmacists | 133 |
clinical presentation | 133 |
university hospital | 132 |
commonly used | 129 |
world health | 126 |
imaging techniques | 126 |
clinical manifestations | 125 |
kg po | 125 |
observational study | 125 |
critical care | 123 |
severe disease | 123 |
imaging modalities | 122 |
one patient | 122 |
viral load | 122 |
lung injury | 121 |
middle east | 121 |
el uso | 121 |
patients infected | 119 |
adverse events | 119 |
differential diagnoses | 119 |
case series | 118 |
ct scan | 118 |
every hours | 118 |
clinical microbiology | 117 |
spinal cord | 117 |
mg dl | 117 |
rheumatoid arthritis | 117 |
coronavirus pneumonia | 117 |
viral infections | 116 |
body weight | 116 |
control group | 115 |
diabetes mellitus | 115 |
high risk | 115 |
randomized clinical | 114 |
pregnant women | 114 |
infected patients | 113 |
will also | 113 |
retrospective cohort | 113 |
controlled trial | 113 |
del paciente | 113 |
within days | 113 |
may include | 112 |
bowel disease | 110 |
portal vein | 110 |
endothelial cells | 110 |
heart disease | 110 |
infected animals | 109 |
clinical pharmacist | 109 |
emergency department | 109 |
large intestine | 109 |
east respiratory | 109 |
antibiotic therapy | 108 |
health organization | 108 |
may require | 108 |
may lead | 108 |
incubation period | 108 |
portal hypertension | 107 |
chain reaction | 106 |
clinical outcomes | 106 |
signs include | 105 |
common cause | 105 |
disease severity | 105 |
clinical disease | 105 |
resonance imaging | 104 |
one may | 104 |
fluid therapy | 104 |
nucleic acid | 104 |
drug administration | 104 |
clinical symptoms | 103 |
descriptive abstract | 103 |
polymerase chain | 102 |
septic shock | 102 |
mast cell | 102 |
liver injury | 101 |
statistically significant | 101 |
pharmaceutical care | 101 |
converting enzyme | 101 |
radiation dose | 101 |
pet birds | 101 |
many cases | 101 |
inflammatory bowel | 100 |
may help | 100 |
transplant recipients | 99 |
least one | 99 |
among patients | 99 |
bone tissue | 99 |
risk factor | 99 |
bile acids | 99 |
urinary tract | 98 |
significantly higher | 98 |
surgical treatment | 98 |
respiratory disease | 98 |
blood cell | 98 |
chest ct | 98 |
drug interactions | 98 |
para el | 97 |
primary care | 96 |
medication reconciliation | 96 |
el paciente | 95 |
periodontal disease | 95 |
small bowel | 95 |
disease may | 95 |
liver biopsy | 95 |
por covid | 95 |
upper respiratory | 94 |
see table | 94 |
mucous membranes | 94 |
hepatic lipidosis | 94 |
may develop | 94 |
bile duct | 94 |
clinical data | 93 |
pulmonary edema | 93 |
animals may | 92 |
con el | 92 |
otitis media | 92 |
coronavirus infection | 91 |
bacterial infection | 91 |
pediatric patients | 90 |
become familiar | 89 |
peritoneal fluid | 89 |
pet ct | 89 |
research complications | 89 |
median age | 88 |
hepatic disease | 88 |
metabolic acidosis | 88 |
viral infection | 88 |
body mass | 87 |
activated charcoal | 86 |
immune responses | 86 |
animal model | 86 |
inflammatory cytokines | 85 |
antimicrobial therapy | 85 |
cell tumors | 85 |
cardiovascular disease | 85 |
renal function | 85 |
patients admitted | 85 |
hospital stay | 85 |
intestinal obstruction | 84 |
randomized controlled | 84 |
infectious disease | 84 |
white blood | 84 |
recent study | 83 |
factors associated | 83 |
intravenous fluids | 83 |
image quality | 83 |
pleural effusion | 82 |
commercially available | 82 |
breast cancer | 82 |
tract infections | 82 |
will discuss | 82 |
less common | 81 |
underlying cause | 81 |
small cell | 81 |
white matter | 81 |
kg day | 81 |
imaging modality | 80 |
adult patients | 80 |
orogastric lavage | 80 |
type i | 80 |
escherichia coli | 80 |
kg body | 80 |
necropsy findings | 79 |
respiratory syncytial | 79 |
poor prognosis | 79 |
may provide | 78 |
acute phase | 77 |
clinical ethics | 77 |
elderly patients | 77 |
amino acid | 77 |
small animal | 77 |
signs may | 77 |
mortality rates | 77 |
patients receiving | 77 |
north america | 77 |
presentation will | 76 |
performed using | 76 |
influenza virus | 76 |
con sospecha | 76 |
large number | 76 |
diagnostic tests | 76 |
red blood | 76 |
blood cells | 76 |
portosystemic shunts | 75 |
even though | 75 |
liver function | 75 |
large colon | 75 |
naturally occurring | 75 |
hepatic encephalopathy | 75 |
disease process | 75 |
case reports | 75 |
within hours | 75 |
widely used | 75 |
higher risk | 75 |
organ failure | 74 |
two groups | 74 |
significant difference | 74 |
sore throat | 73 |
clostridium difficile | 73 |
internal medicine | 73 |
new york | 73 |
direct contact | 73 |
medical records | 73 |
viral replication | 72 |
lymph node | 72 |
may become | 72 |
syncytial virus | 72 |
imaging features | 72 |
wide range | 72 |
informed consent | 72 |
portosystemic shunting | 72 |
diagnostic imaging | 72 |
liver enzymes | 71 |
paciente con | 71 |
clinical management | 71 |
effective treatment | 71 |
sin embargo | 71 |
general anesthesia | 71 |
patients received | 70 |
respiratory rate | 70 |
laboratory tests | 70 |
case history | 70 |
hepatobiliary disease | 70 |
whenever possible | 70 |
clinically relevant | 70 |
dental schools | 69 |
abdominal wall | 69 |
diagnostic accuracy | 69 |
pharmacy services | 69 |
type diabetes | 69 |
monoclonal antibody | 69 |
symptom onset | 69 |
brain injury | 69 |
supplemental oxygen | 68 |
arterial blood | 68 |
per day | 68 |
medication adherence | 68 |
patient safety | 68 |
medical center | 68 |
cell carcinoma | 68 |
pilot study | 68 |
prospective study | 68 |
common clinical | 68 |
determine whether | 68 |
antiviral activity | 68 |
chronic disease | 67 |
whole blood | 67 |
sample size | 67 |
growth factor | 67 |
life cycle | 67 |
body temperature | 66 |
trauma center | 66 |
laboratory findings | 66 |
many patients | 66 |
another study | 66 |
may reveal | 66 |
human beings | 66 |
con un | 66 |
laboratory animal | 66 |
hepatic copper | 66 |
care units | 65 |
biliary tract | 65 |
liver diseases | 65 |
drug therapy | 65 |
gold standard | 65 |
may appear | 65 |
clinical study | 65 |
last years | 65 |
sars coronavirus | 65 |
treatment options | 65 |
descriptive study | 64 |
dental care | 64 |
ace expression | 64 |
lung disease | 64 |
mm hg | 64 |
peripheral blood | 64 |
per patient | 64 |
investigation results | 64 |
significantly lower | 64 |
lower respiratory | 63 |
surgical intervention | 63 |
staphylococcus aureus | 63 |
included patients | 63 |
see section | 63 |
spike protein | 63 |
recent years | 63 |
one must | 63 |
retrospective review | 63 |
intestinal tract | 62 |
en un | 62 |
cov infection | 62 |
fatality rate | 62 |
bacterial infections | 62 |
smooth muscle | 62 |
intravascular coagulation | 62 |
reactive protein | 62 |
blood glucose | 62 |
kidney disease | 62 |
clinically significant | 62 |
fatty acids | 62 |
myocardial infarction | 62 |
findings include | 62 |
rna polymerase | 61 |
inclusion criteria | 61 |
perfringens type | 61 |
compassionate use | 61 |
significant differences | 61 |
laboratory animals | 61 |
will review | 61 |
disseminated intravascular | 61 |
recent studies | 61 |
pediatric radiology | 61 |
secondary bacterial | 60 |
see chapter | 60 |
cell count | 60 |
early diagnosis | 60 |
bile ducts | 60 |
twice daily | 60 |
imaging studies | 60 |
two patients | 60 |
alt activity | 60 |
gastrointestinal disease | 59 |
susceptibility testing | 59 |
psittacine birds | 59 |
ct findings | 59 |
literature review | 59 |
weighted imaging | 59 |
surgical resection | 59 |
clinical specimens | 59 |
pao fio | 58 |
clostridium perfringens | 58 |
rib fractures | 58 |
con una | 58 |
disease control | 58 |
national health | 58 |
cardiac output | 58 |
radiation exposure | 58 |
patients hospitalized | 58 |
nitric oxide | 58 |
viral rna | 57 |
clinical response | 57 |
ebola virus | 57 |
pathologic findings | 57 |
study clinical | 57 |
antibiotic treatment | 57 |
liver enzyme | 57 |
controlled trials | 57 |
complete blood | 57 |
antibiotic resistance | 57 |
also occur | 57 |
may present | 57 |
average age | 57 |
disease activity | 56 |
oxygen saturation | 56 |
infectious agents | 56 |
united kingdom | 56 |
tract infection | 56 |
underlying disease | 56 |
respiratory infections | 56 |
contrast agents | 56 |
minimally invasive | 56 |
blood gas | 56 |
cell lymphoma | 56 |
early stages | 56 |
surgical procedures | 56 |
small ruminants | 56 |
disease progression | 55 |
interventional radiology | 55 |
aspiration pneumonia | 55 |
liver failure | 55 |
high doses | 55 |
blood culture | 55 |
por sars | 55 |
el manejo | 55 |
also known | 55 |
lung cancer | 55 |
mass spectrometry | 55 |
may contribute | 55 |
cancer patients | 55 |
age group | 55 |
control measures | 55 |
adult horses | 54 |
injury severity | 54 |
currently available | 54 |
several days | 54 |
se debe | 54 |
test results | 54 |
squamous cell | 54 |
intravenous fluid | 54 |
clinical setting | 54 |
coronary artery | 54 |
hepatic injury | 54 |
chronic diseases | 54 |
data collection | 54 |
clinical use | 53 |
clinical applications | 53 |
community pharmacies | 53 |
innate immune | 53 |
congenital heart | 53 |
acute lung | 53 |
will help | 53 |
oral cavity | 53 |
ct angiography | 52 |
accurate diagnosis | 52 |
infection control | 52 |
nonsteroidal antiinflammatory | 52 |
community pharmacy | 52 |
reperfusion injury | 52 |
se ha | 52 |
confirmed cases | 52 |
pacientes en | 52 |
el riesgo | 52 |
hepatic necrosis | 52 |
may play | 52 |
medical management | 52 |
increased serum | 52 |
predictive value | 52 |
amino acids | 52 |
clinical outcome | 51 |
patients undergoing | 51 |
ct scans | 51 |
related problems | 51 |
clinical laboratory | 51 |
abdominal cavity | 51 |
tissue damage | 51 |
un estudio | 51 |
clinical information | 51 |
medical treatment | 51 |
mg ml | 51 |
large intestinal | 51 |
rhesus macaques | 51 |
large numbers | 51 |
statistical analysis | 51 |
adverse drug | 50 |
multiple organ | 50 |
mesenchymal stromal | 50 |
animals will | 50 |
por el | 50 |
antiviral drugs | 50 |
infection may | 50 |
large amounts | 50 |
study period | 50 |
several studies | 50 |
hospital mortality | 50 |
radiation therapy | 49 |
medical imaging | 49 |
time pcr | 49 |
cytokine release | 49 |
common causes | 49 |
cell therapy | 49 |
ct imaging | 49 |
inflammatory mediators | 49 |
blood count | 49 |
vena cava | 49 |
cell types | 49 |
west nile | 49 |
high mortality | 49 |
clinical samples | 49 |
solid organ | 49 |
systemic inflammation | 49 |
hepatocellular carcinoma | 49 |
feline infectious | 49 |
cerebrospinal fluid | 49 |
one case | 49 |
american college | 49 |
study group | 49 |
benefi ts | 49 |
inflammatory disease | 48 |
high levels | 48 |
streptococcal pharyngitis | 48 |
will provide | 48 |
new coronavirus | 48 |
emergency surgery | 48 |
year old | 48 |
traditional chinese | 48 |
molecular imaging | 48 |
monoclonal antibodies | 48 |
vertical transmission | 48 |
acute pancreatitis | 48 |
gastric ulceration | 48 |
blood samples | 48 |
retrospective analysis | 48 |
therapy may | 48 |
neurologic signs | 48 |
tumour response | 48 |
single center | 48 |
less likely | 48 |
signs associated | 48 |
patients presented | 47 |
induce emesis | 47 |
blood loss | 47 |
observational studies | 47 |
may increase | 47 |
type ii | 47 |
surgical management | 47 |
protease inhibitors | 47 |
early stage | 47 |
colorectal cancer | 47 |
beneficial effects | 47 |
passive transfer | 47 |
systemic inflammatory | 47 |
gastric ulcers | 47 |
endothelial cell | 47 |
broad spectrum | 47 |
hemolytic anemia | 47 |
host cell | 47 |
chinese medicine | 47 |
health professionals | 47 |
gastric emptying | 47 |
functional imaging | 47 |
sectional imaging | 47 |
per year | 47 |
bacterial pneumonia | 47 |
genome sequencing | 47 |
whole body | 47 |
mast cells | 47 |
old male | 47 |
qt interval | 47 |
infectious peritonitis | 47 |
first case | 46 |
clinical chemistry | 46 |
therapeutic agents | 46 |
health system | 46 |
parainfluenza virus | 46 |
abdominal ultrasound | 46 |
hospital admission | 46 |
hepatic failure | 46 |
plasma therapy | 46 |
se puede | 46 |
chronic liver | 46 |
nutritional support | 46 |
intestinal mucosa | 46 |
respiratory viruses | 46 |
young children | 46 |
stromal cells | 46 |
patients may | 46 |
lesions may | 46 |
crystalloid fluids | 46 |
patient outcomes | 46 |
electrolyte abnormalities | 45 |
study showed | 45 |
healthcare professionals | 45 |
pediatric population | 45 |
ml min | 45 |
myocardial injury | 45 |
cardiovascular system | 45 |
confirmed covid | 45 |
pulmonary embolism | 45 |
kg orally | 45 |
cuidados intensivos | 45 |
sudden death | 45 |
combination therapy | 45 |
clinical impact | 45 |
extracellular vesicles | 45 |
specific treatment | 45 |
year period | 45 |
clinical evidence | 45 |
congestive heart | 45 |
china clinical | 45 |
care workers | 45 |
icu admission | 45 |
multidisciplinary team | 45 |
also found | 44 |
respiratory symptoms | 44 |
nuclear medicine | 44 |
decision making | 44 |
long term | 44 |
severity score | 44 |
ill covid | 44 |
dengue virus | 44 |
dental education | 44 |
patients presenting | 44 |
invasive mechanical | 44 |
acute renal | 44 |
inflammatory diseases | 44 |
identifi cation | 44 |
urine output | 44 |
cell death | 44 |
alp activity | 44 |
en las | 44 |
patients without | 44 |
medical devices | 44 |
two different | 44 |
first step | 44 |
viral loads | 44 |
severe pneumonia | 44 |
treatment consists | 44 |
gastrointestinal symptoms | 44 |
cause severe | 44 |
infected pneumonia | 44 |
traumatic brain | 44 |
clinical sign | 44 |
perform orogastric | 44 |
data collected | 44 |
clinical progression | 44 |
virus disease | 43 |
drug repurposing | 43 |
hospital discharge | 43 |
renal disease | 43 |
mononuclear cells | 43 |
organ dysfunction | 43 |
clin chem | 43 |
soft tissues | 43 |
first week | 43 |
clinical evaluation | 43 |
acute hepatitis | 43 |
medical history | 43 |
clinical relevance | 43 |
patient management | 43 |
logistic regression | 43 |
contrast agent | 43 |
spectrum antibiotics | 43 |
examination findings | 43 |
oral administration | 43 |
treatment may | 43 |
clinically normal | 43 |
middle ear | 43 |
kidney injury | 43 |
acute abdominal | 43 |
electron microscopy | 43 |
ng ml | 43 |
may need | 43 |
key role | 43 |
el grupo | 43 |
drug development | 43 |
clinical efficacy | 42 |
disease course | 42 |
el tratamiento | 42 |
severely affected | 42 |
immunodeficiency virus | 42 |
closely related | 42 |
breast imaging | 42 |
sodium bicarbonate | 42 |
therapeutic efficacy | 42 |
nasogastric tube | 42 |
peritoneal cavity | 42 |
umbilical cord | 42 |
may show | 42 |
nasal discharge | 42 |
integrative medicine | 42 |
teaching hospital | 42 |
antiinflammatory drugs | 42 |
administer intravenous | 42 |
central venous | 42 |
often associated | 42 |
therapeutic options | 42 |
patients diagnosed | 42 |
clinical significance | 42 |
doberman pinschers | 42 |
gi tract | 42 |
hubei province | 42 |
natural history | 42 |
alkaline phosphatase | 42 |
acute onset | 41 |
septic peritonitis | 41 |
severe respiratory | 41 |
initial treatment | 41 |
kg hour | 41 |
young animals | 41 |
study reported | 41 |
mri findings | 41 |
biopsy samples | 41 |
lesions include | 41 |
copper accumulation | 41 |
viral shedding | 41 |
vascular permeability | 41 |
necrosis factor | 41 |
neutralizing antibodies | 41 |
medical care | 41 |
rectal prolapse | 41 |
parenteral nutrition | 41 |
coronavirus infections | 40 |
quality control | 40 |
linear foreign | 40 |
human transmission | 40 |
research setting | 40 |
induced liver | 40 |
nile virus | 40 |
imaging plays | 40 |
frequently used | 40 |
icu patients | 40 |
immune function | 40 |
mesenteric lymph | 40 |
vast majority | 40 |
treatment response | 40 |
immune cells | 40 |
host cells | 40 |
potential therapeutic | 40 |
european countries | 40 |
study found | 40 |
affected dogs | 40 |
flunixin meglumine | 40 |
national institute | 40 |
good clinical | 40 |
dose reduction | 40 |
spatial resolution | 40 |
chest wall | 40 |
four patients | 40 |
two cases | 40 |
abdominal distention | 40 |
frozen plasma | 40 |
different types | 40 |
intestinal disease | 40 |
pharmaceutical interventions | 40 |
host immune | 39 |
needle aspiration | 39 |
corticosteroid therapy | 39 |
older patients | 39 |
clinical cases | 39 |
surgical correction | 39 |
plasma convaleciente | 39 |
blood cultures | 39 |
blunt trauma | 39 |
small number | 39 |
por lo | 39 |
lecture will | 39 |
passive immunity | 39 |
community pharmacists | 39 |
dependent rna | 39 |
posterior fossa | 39 |
viral clearance | 39 |
imaging technique | 39 |
age years | 39 |
urinary bladder | 39 |
blood transfusion | 39 |
cardiac arrest | 39 |
median time | 39 |
growth factors | 39 |
large animal | 39 |
abdominal radiographs | 39 |
rhodococcus equi | 39 |
respiratory infection | 39 |
randomised controlled | 39 |
early detection | 39 |
working group | 38 |
mouse model | 38 |
intestinal wall | 38 |
en una | 38 |
often present | 38 |
dental insurance | 38 |
acute kidney | 38 |
enzyme activities | 38 |
supportive therapy | 38 |
antimicrobial agents | 38 |
cell membrane | 38 |
en cuenta | 38 |
inflammatory cells | 38 |
causative agent | 38 |
dynamic contrast | 38 |
will focus | 38 |
proton pump | 38 |
clinical history | 38 |
severe clinical | 38 |
protective equipment | 38 |
blood volume | 38 |
abdominal trauma | 38 |
scoring system | 38 |
also used | 38 |
cervical spine | 38 |
receptor antagonist | 38 |
gram negative | 38 |
infected birds | 38 |
juvenile idiopathic | 38 |
body condition | 38 |
high level | 38 |
ethylene glycol | 37 |
older adults | 37 |
blood vessels | 37 |
adipose tissue | 37 |
portal venous | 37 |
intravenous immunoglobulin | 37 |
hemorrhagic fever | 37 |
carbon dioxide | 37 |
diaphragmatic hernia | 37 |
phase i | 37 |
may predispose | 37 |
negative bacteria | 37 |
wide variety | 37 |
serum bile | 37 |
idiopathic arthritis | 37 |
kg minute | 37 |
mucosal injury | 37 |
readily available | 37 |
drug reactions | 37 |
negative pressure | 37 |
disease caused | 37 |
liver tissue | 37 |
pulmonary disease | 37 |
severe patients | 37 |
hong kong | 37 |
avian influenza | 37 |
medical device | 37 |
case fatality | 37 |
clinical settings | 37 |
large bowel | 37 |
antimicrobial resistance | 37 |
perfusion imaging | 37 |
patient population | 37 |
clinical diagnosis | 37 |
may affect | 37 |
often used | 37 |
presumptive diagnosis | 37 |
included studies | 37 |
made available | 36 |
esophageal sphincter | 36 |
make sure | 36 |
blood ammonia | 36 |
biomedical research | 36 |
clinical benefit | 36 |
neonatal foals | 36 |
wound healing | 36 |
bacterial pathogens | 36 |
severely ill | 36 |
personal protective | 36 |
patients showed | 36 |
viral pneumonia | 36 |
chronic inflammation | 36 |
health insurance | 36 |
emergency care | 36 |
hepatic fibrosis | 36 |
crucial role | 36 |
kawasaki disease | 36 |
pulmonary artery | 36 |
ground glass | 36 |
chronic inflammatory | 36 |
prostate cancer | 36 |
occurs within | 36 |
release syndrome | 36 |
diagnostic criteria | 36 |
fresh frozen | 36 |
many years | 36 |
affected foals | 36 |
salmonella spp | 36 |
clinical decision | 36 |
well tolerated | 36 |
clinical experience | 36 |
serum alt | 36 |
among others | 36 |
metabolic syndrome | 36 |
occur within | 36 |
per rectum | 36 |
severely injured | 36 |
vascular access | 35 |
mr images | 35 |
less severe | 35 |
skin lesions | 35 |
affected cats | 35 |
adverse reactions | 35 |
pathological findings | 35 |
commonly associated | 35 |
airway obstruction | 35 |
diagnostic test | 35 |
may induce | 35 |
nursing home | 35 |
additional information | 35 |
bile acid | 35 |
experimentally induced | 35 |
platelet count | 35 |
also possible | 35 |
mechanically ventilated | 35 |
different imaging | 35 |
term survival | 35 |
congenital portosystemic | 35 |
low doses | 35 |
total number | 35 |
pharmacy practice | 35 |
successful treatment | 35 |
takes place | 35 |
chronic kidney | 35 |
organ transplant | 35 |
tumor necrosis | 35 |
trauma care | 35 |
pulse oximetry | 35 |
normal range | 35 |
bone graft | 35 |
atrial fibrillation | 35 |
inflammatory markers | 35 |
current evidence | 35 |
pharmacy department | 35 |
lupus erythematosus | 35 |
bedlington terriers | 35 |
significantly reduced | 34 |
session will | 34 |
electronic health | 34 |
may indicate | 34 |
small colon | 34 |
vascular anomalies | 34 |
gene expression | 34 |
acute pharyngitis | 34 |
five patients | 34 |
inflammatory drugs | 34 |
therapeutic effect | 34 |
autoimmune diseases | 34 |
may benefit | 34 |
plasma cells | 34 |
neurological signs | 34 |
common finding | 34 |
intended use | 34 |
clinical laboratories | 34 |
gauge needle | 34 |
imaging methods | 34 |
phase trial | 34 |
associated pneumonia | 34 |
oxygen therapy | 34 |
treatment planning | 34 |
adjunctive therapy | 34 |
electrolyte imbalances | 34 |
literature search | 34 |
toxoplasma gondii | 34 |
safety profile | 34 |
cell entry | 34 |
disease processes | 34 |
experimental studies | 34 |
pharmaceutical companies | 34 |
intravenous crystalloid | 34 |
surface area | 34 |
will require | 34 |
specific clinical | 34 |
trauma registry | 34 |
three times | 34 |
encephalitis virus | 34 |
fungal infections | 34 |
coronary heart | 34 |
become infected | 34 |
new drug | 34 |
major trauma | 34 |
treatment strategies | 34 |
oral route | 34 |
left ventricular | 34 |
general population | 34 |
appropriate treatment | 33 |
patients using | 33 |
brain mri | 33 |
surgical removal | 33 |
ischemic stroke | 33 |
receptor blockers | 33 |
transit time | 33 |
spectrum antiviral | 33 |
three patients | 33 |
con los | 33 |
biopsy specimens | 33 |
significantly increased | 33 |
chest radiograph | 33 |
systemic lupus | 33 |
exploratory laparotomy | 33 |
packed cell | 33 |
needle biopsy | 33 |
neonatal isoerythrolysis | 33 |
health emergency | 33 |
emergency use | 33 |
made based | 33 |
diarrhea may | 33 |
lower esophageal | 33 |
overall mortality | 33 |
prone positioning | 33 |
surgical techniques | 33 |
intermediate host | 33 |
drug related | 33 |
enzyme activity | 33 |
evidence suggests | 33 |
cell culture | 33 |
local anesthetic | 33 |
plasma protein | 33 |
response rate | 33 |
clinical educators | 33 |
thoracic radiographs | 33 |
recent advances | 33 |
may reduce | 33 |
proinflammatory cytokines | 33 |
cardiovascular diseases | 33 |
acute liver | 33 |
day mortality | 33 |
lg ml | 33 |
past years | 33 |
zoonotic potential | 33 |
one year | 33 |
practice guidelines | 33 |
predisposing factors | 33 |
internal fixation | 33 |
ct images | 33 |
common cold | 33 |
central role | 33 |
pulmonary hypertension | 33 |
research studies | 33 |
cerebral edema | 33 |
high concentrations | 33 |
findings may | 33 |
tertiary care | 33 |
hospital pharmacy | 32 |
clinical pharmacology | 32 |
oncotic pressure | 32 |
high prevalence | 32 |
laboratory test | 32 |
less commonly | 32 |
tissue perfusion | 32 |
study design | 32 |
healthcare system | 32 |
refill time | 32 |
drinking water | 32 |
urinary catheter | 32 |
respiratory viral | 32 |
older animals | 32 |
head trauma | 32 |
phase iii | 32 |
also reported | 32 |
care professionals | 32 |
routine clinical | 32 |
adult inpatients | 32 |
mild cases | 32 |
take care | 32 |
organ systems | 32 |
information regarding | 32 |
incidental findings | 32 |
blood stasis | 32 |
comparative study | 32 |
renal impairment | 32 |
disease patients | 32 |
prognostic factors | 32 |
clinical isolates | 32 |
global health | 32 |
intermediate hosts | 32 |
operating room | 32 |
passerine birds | 32 |
regional anesthesia | 32 |
diagnostic workup | 32 |
special attention | 32 |
conservative treatment | 32 |
clinical audit | 32 |
present study | 32 |
high resolution | 32 |
acute hepatic | 32 |
capillary refill | 32 |
loading dose | 32 |
care providers | 32 |
pump inhibitors | 32 |
todos los | 32 |
bordetella bronchiseptica | 32 |
experimentally infected | 32 |
small animals | 31 |
vascular injury | 31 |
fluorescent antibody | 31 |
several weeks | 31 |
blood products | 31 |
corona virus | 31 |
consecutive patients | 31 |
multicenter study | 31 |
less frequently | 31 |
clinical care | 31 |
nipah virus | 31 |
randomized trial | 31 |
quality assurance | 31 |
cell volume | 31 |
cranial nerve | 31 |
radiographs may | 31 |
preliminary report | 31 |
gastric acid | 31 |
total body | 31 |
may improve | 31 |
creatine kinase | 31 |
rabies virus | 31 |
child abuse | 31 |
new drugs | 31 |
ovarian cancer | 31 |
chest pain | 31 |
tyrosine kinase | 31 |
low dose | 31 |
early phase | 31 |
pelvic floor | 31 |
individual patient | 31 |
protein concentration | 31 |
ulcer disease | 31 |
retrospective observational | 31 |
fetal mri | 31 |
clinical examination | 31 |
healthy cats | 31 |
lactate dehydrogenase | 31 |
endemic areas | 31 |
paediatric patients | 31 |
alveolar damage | 31 |
medical record | 31 |
near future | 31 |
social media | 31 |
usually occurs | 31 |
corticosteroid treatment | 31 |
will include | 31 |
vein thrombosis | 31 |
difficile infection | 31 |
prospective cohort | 31 |
mammary gland | 31 |
cell counts | 31 |
acquired pneumonia | 31 |
saline solution | 31 |
care medicine | 31 |
social distancing | 31 |
demographic data | 31 |
systemic disease | 31 |
constant rate | 31 |
contrast enhanced | 31 |
major cause | 31 |
high sensitivity | 31 |
studies reported | 31 |
elevated serum | 31 |
tissue injury | 31 |
wild birds | 31 |
affected area | 31 |
severe illness | 31 |
cardiac injury | 31 |
institutional review | 31 |
significant improvement | 31 |
previous studies | 30 |
medical therapy | 30 |
cats may | 30 |
also important | 30 |
clinical syndromes | 30 |
quality improvement | 30 |
bowel obstruction | 30 |
hepatic dysfunction | 30 |
cell surface | 30 |
mg day | 30 |
cause diarrhea | 30 |
signal intensity | 30 |
primary outcome | 30 |
clinical illness | 30 |
open reduction | 30 |
treated patients | 30 |
signifi cant | 30 |
microbiology laboratories | 30 |
virus infections | 30 |
hemorrhagic shock | 30 |
study using | 30 |
interstitial lung | 30 |
oxygen delivery | 30 |
molecular weight | 30 |
veterinary medicine | 30 |
pharmacist intervention | 30 |
significant increase | 30 |
dry weight | 30 |
en uci | 30 |
high rate | 30 |
south america | 30 |
different countries | 30 |
antiviral therapy | 30 |
first line | 30 |
will present | 30 |
severe coronavirus | 30 |
results showed | 30 |
hepatic parenchyma | 30 |
culture results | 30 |
lamina propria | 30 |
body fluids | 30 |
sectional study | 30 |
en su | 30 |
hospitalised patients | 30 |
data analysis | 30 |
hiv infection | 30 |
last decade | 30 |
jugular vein | 30 |
left shift | 30 |
exclusion criteria | 30 |
cost savings | 30 |
gastric mucosa | 30 |
clinical syndrome | 30 |
femoral neck | 30 |
clinical application | 30 |
patients suffering | 30 |
se han | 30 |
blood supply | 30 |
medical education | 30 |
feeding tube | 30 |
interstitial pneumonia | 29 |
connective tissue | 29 |
stool samples | 29 |
response syndrome | 29 |
commonly found | 29 |
resistance genes | 29 |
health commission | 29 |
iu kg | 29 |
gi symptoms | 29 |
general surgery | 29 |
electronic medical | 29 |
los estudios | 29 |
orally every | 29 |
secondary infection | 29 |
will increase | 29 |
dose adjustment | 29 |
plasma concentrations | 29 |
will allow | 29 |
also cause | 29 |
human disease | 29 |
leading cause | 29 |
radiation protection | 29 |
seven patients | 29 |
su uso | 29 |
multidisciplinary approach | 29 |
angiotensin ii | 29 |
gastroesophageal reflux | 29 |
linked immunosorbent | 29 |
optic neuritis | 29 |
first hours | 29 |
drug treatment | 29 |
days later | 29 |
gross lesions | 29 |
diagnosis may | 29 |
intestinal motility | 29 |
fi ndings | 29 |
septic arthritis | 29 |
systolic blood | 29 |
contaminated food | 29 |
per os | 29 |
inhalational anthrax | 29 |
findings will | 29 |
will continue | 29 |
vaccine development | 29 |
intravenous catheter | 29 |
infection prevention | 29 |
will need | 29 |
maintain hydration | 29 |
significantly different | 29 |
immunosorbent assay | 29 |
gestational age | 29 |
study demonstrated | 29 |
may produce | 29 |
treating covid | 29 |
hearing loss | 29 |
medication review | 29 |
oxidative stress | 29 |
acute care | 29 |
prothrombin time | 29 |
treatment option | 29 |
imaging biomarkers | 29 |
spike glycoprotein | 29 |
may prevent | 29 |
future studies | 29 |
cases may | 29 |
bacterial culture | 29 |
optic nerve | 29 |
many clinical | 29 |
survival time | 29 |
liver damage | 28 |
several months | 28 |
study included | 28 |
routine use | 28 |
klebsiella pneumoniae | 28 |
ascending colon | 28 |
include vomiting | 28 |
warm water | 28 |
vascular endothelial | 28 |
trauma team | 28 |
diagnostic tool | 28 |
oral transmission | 28 |
clotting factors | 28 |
right dorsal | 28 |
commonly affected | 28 |
higher mortality | 28 |
fecal samples | 28 |
radiological findings | 28 |
cynomolgus macaques | 28 |
sterile saline | 28 |
weight gain | 28 |
york city | 28 |
healthcare workers | 28 |
disease virus | 28 |
patients reported | 28 |
pelvic fractures | 28 |
alanine aminotransferase | 28 |
chronic pancreatitis | 28 |
rate infusion | 28 |
lower extremity | 28 |
pediatric radiologists | 28 |
will likely | 28 |
positive results | 28 |
early clinical | 28 |
tissue samples | 28 |
cohort studies | 28 |
debe ser | 28 |
con sdra | 28 |
first time | 28 |
patient age | 28 |
real time | 28 |
artery disease | 28 |
weighted images | 28 |
educational content | 28 |
hypovolemic shock | 28 |
protease inhibitor | 28 |
como el | 28 |
cell lines | 28 |
interim guidance | 28 |
pseudomonas aeruginosa | 28 |
diagnostic testing | 28 |
individual patients | 28 |
experimental models | 28 |
pregnancy toxemia | 28 |
respiratory signs | 28 |
adults hospitalized | 28 |
diagnoses include | 28 |
may explain | 28 |
cardiac disease | 28 |
human immunodeficiency | 28 |
burn injury | 28 |
nodular hyperplasia | 28 |
young adults | 28 |
first described | 28 |
abdominal fluid | 28 |
laboratory testing | 28 |
chronic pain | 28 |
patients included | 28 |
include fever | 28 |
patient characteristics | 28 |
ongoing clinical | 28 |
serum creatinine | 28 |
may vary | 28 |
positive blood | 28 |
i will | 28 |
mg twice | 28 |
borrelia burgdorferi | 27 |
preventive measures | 27 |
acute coronary | 27 |
analysis showed | 27 |
mental health | 27 |
canine distemper | 27 |
one report | 27 |
within weeks | 27 |
puede ser | 27 |
antibody response | 27 |
drug delivery | 27 |
intravenous infusion | 27 |
show signs | 27 |
nocturnal enuresis | 27 |
es un | 27 |
pharmacy service | 27 |
well known | 27 |
sars patients | 27 |
task force | 27 |
cesarean section | 27 |
emergency room | 27 |
age groups | 27 |
imaging may | 27 |
aortic arch | 27 |
potential benefits | 27 |
survival rate | 27 |
available data | 27 |
pictorial review | 27 |
particularly important | 27 |
campylobacter jejuni | 27 |
image gently | 27 |
acute appendicitis | 27 |
mechanical properties | 27 |
systemic signs | 27 |
weak recommendation | 27 |
dry cough | 27 |
patient data | 27 |
drugs may | 27 |
ventilated patients | 27 |
basement membrane | 27 |
authors declare | 27 |
major role | 27 |
common bile | 27 |
bronchoalveolar lavage | 27 |
lactic acidosis | 27 |
treatment group | 27 |
medication errors | 27 |
chronic diarrhea | 27 |
del virus | 27 |
antibody titers | 27 |
also observed | 27 |
hepatic abscesses | 27 |
th century | 27 |
clinical presentations | 27 |
several factors | 27 |
liver dysfunction | 27 |
drug use | 27 |
diagnostic value | 27 |
data suggest | 27 |
microbiology laboratory | 27 |
fluid collections | 27 |
expert opinion | 27 |
human coronavirus | 27 |
rheumatic fever | 27 |
studies suggest | 27 |
generation sequencing | 27 |
therapeutic strategies | 27 |
mass index | 26 |
respiratory system | 26 |
clinical assessment | 26 |
equine encephalitis | 26 |
increased mortality | 26 |
clinical conditions | 26 |
cardiac dysrhythmias | 26 |
tract disease | 26 |
labrador retrievers | 26 |
negative results | 26 |
mucous membrane | 26 |
commonly seen | 26 |
least two | 26 |
enteral nutrition | 26 |
increasingly used | 26 |
plasminogen activator | 26 |
kg intravenously | 26 |
virus isolation | 26 |
abdominal mass | 26 |
different species | 26 |
will often | 26 |
phase ii | 26 |
lyme disease | 26 |
animal species | 26 |
pharmacy education | 26 |
reactive oxygen | 26 |
potential drug | 26 |
preclinical studies | 26 |
family members | 26 |
month period | 26 |
health status | 26 |
catheter placement | 26 |
polytrauma patients | 26 |
physical activity | 26 |
sendai virus | 26 |
ethics support | 26 |
aspartate aminotransferase | 26 |
antiviral drug | 26 |
mucosal barrier | 26 |
case studies | 26 |
mass casualty | 26 |
patients underwent | 26 |
years ago | 26 |
abdominal ct | 26 |
chronic sinusitis | 26 |
european medicines | 26 |
urea nitrogen | 26 |
serum albumin | 26 |
may involve | 26 |
interferon beta | 26 |
biliary obstruction | 26 |
skeletal muscle | 26 |
negative predictive | 26 |
within normal | 26 |
infection rates | 26 |
clinical parameters | 26 |
cardiac ct | 26 |
receptor antagonists | 26 |
granulomatous enteritis | 26 |
surgical excision | 26 |
small sample | 26 |
may act | 26 |
patients will | 26 |
also present | 26 |
lung transplant | 26 |
chest radiography | 26 |
severe ards | 26 |
intrahepatic cholestasis | 26 |
contrast enhancement | 26 |
positive impact | 26 |
medicines agency | 26 |
muscle tremors | 26 |
standard care | 26 |
intestinal contents | 26 |
critical illness | 26 |
hip fracture | 26 |
systematic reviews | 26 |
first months | 26 |
high dose | 26 |
intravenous administration | 26 |
first year | 26 |
genetic testing | 26 |
primary cause | 26 |
pcr testing | 26 |
mammary tumors | 26 |
within minutes | 26 |
imaging characteristics | 26 |
old female | 26 |
family history | 26 |
el cual | 26 |
atopic dermatitis | 26 |
clinical utility | 26 |
complications associated | 26 |
potential risk | 26 |
odds ratio | 26 |
many studies | 26 |
progenitor cells | 26 |
better understanding | 26 |
cytologic examination | 26 |
msc therapies | 26 |
surgical exploration | 26 |
sodium chloride | 25 |
ionising radiation | 25 |
function tests | 25 |
high quality | 25 |
center study | 25 |
prognostic value | 25 |
kg sq | 25 |
cuidado intensivo | 25 |
low risk | 25 |
controlled clinical | 25 |
domestic animals | 25 |
acute infection | 25 |
disease occurs | 25 |
study shows | 25 |
measured using | 25 |
animal practice | 25 |
veterinary therapy | 25 |
vaginal discharge | 25 |
squamous mucosa | 25 |
publication bias | 25 |
wide spectrum | 25 |
symptomatic patients | 25 |
antibiotic use | 25 |
ethics committee | 25 |
chronic bronchitis | 25 |
commonly observed | 25 |
qt prolongation | 25 |
standard treatment | 25 |
control study | 25 |
improve patient | 25 |
experimental infection | 25 |
fibrous tissue | 25 |
operative management | 25 |
six patients | 25 |
may prove | 25 |
success rate | 25 |
femoral head | 25 |
diagnostic approach | 25 |
naturally infected | 25 |
infectious bovine | 25 |
antimicrobial susceptibility | 25 |
many cats | 25 |
may serve | 25 |
cord injury | 25 |
may take | 25 |
critical role | 25 |
iv cri | 25 |
drug resistance | 25 |
liver transplantation | 25 |
en este | 25 |
risk assessment | 25 |
human patients | 25 |
neurological symptoms | 25 |
increased levels | 25 |
patients aged | 25 |
aged years | 25 |
diffuse alveolar | 25 |
new zealand | 25 |
extrahepatic biliary | 25 |
innate immunity | 25 |
el inicio | 25 |
will show | 25 |
primary liver | 25 |
studies may | 25 |
cerebrovascular disease | 25 |
coagulation parameters | 25 |
collected data | 25 |
drug discovery | 25 |
label use | 25 |
imaging protocols | 25 |
study population | 25 |
viral diseases | 25 |
main protease | 25 |
zika virus | 25 |
pelvic flexure | 25 |
diagnosis requires | 25 |
lessons learned | 25 |
hemodynamically stable | 25 |
endotracheal intubation | 25 |
renal tubular | 25 |
will become | 25 |
important part | 25 |
mycobacterium tuberculosis | 25 |
tight junction | 25 |
el momento | 25 |
risk patients | 25 |
caudal vena | 25 |
brain barrier | 25 |
male dogs | 25 |
viral diarrhea | 25 |
income countries | 25 |
current veterinary | 25 |
chronic obstructive | 25 |
review board | 25 |
six months | 25 |
age range | 25 |
previously described | 25 |
drug monitoring | 24 |
cell membranes | 24 |
th day | 24 |
cell lung | 24 |
fecal flotation | 24 |
commonly reported | 24 |
agents may | 24 |
hospital pharmacists | 24 |
potential treatment | 24 |
approximately days | 24 |
phase clinical | 24 |
feline liver | 24 |
respiratory support | 24 |
rat model | 24 |
malignant lesions | 24 |
clinical indications | 24 |
endotracheal tube | 24 |
cell wall | 24 |
en contra | 24 |
targeted therapies | 24 |
viral entry | 24 |
sobre el | 24 |
label non | 24 |
higher incidence | 24 |
causative organism | 24 |
causes include | 24 |
different clinical | 24 |
systemic circulation | 24 |
may allow | 24 |
results suggest | 24 |
high morbidity | 24 |
like disease | 24 |
diabetic patients | 24 |
liver may | 24 |
treatment failure | 24 |
chronic infection | 24 |
infections may | 24 |
pulmonary arterial | 24 |
chloroquine phosphate | 24 |
mustela putorius | 24 |
regression analysis | 24 |
positive patients | 24 |
human infection | 24 |
health services | 24 |
clinical results | 24 |
complement system | 24 |
upper airway | 24 |
cause clinical | 24 |
ace inhibitors | 24 |
data regarding | 24 |
also shown | 24 |
much higher | 24 |
contrast radiography | 24 |
useful tool | 24 |
well established | 24 |
functional outcome | 24 |
retrospectively reviewed | 24 |
rna viruses | 24 |
cell therapies | 24 |
ventricular tachycardia | 24 |
toxic effects | 24 |
varying degrees | 24 |
highly sensitive | 24 |
improved outcomes | 24 |
potential role | 24 |
first reported | 24 |
initial clinical | 24 |
small amounts | 24 |
injured patients | 24 |
improve clinical | 24 |
diffusion weighted | 24 |
early recognition | 24 |
high incidence | 24 |
important cause | 24 |
transplant patients | 24 |
asymptomatic patients | 24 |
chronic conditions | 24 |
medical staff | 24 |
also seen | 24 |
helicobacter spp | 24 |
antiviral agents | 24 |
two weeks | 24 |
derived mesenchymal | 24 |
blood circulation | 24 |
membrane oxygenation | 24 |
amazon parrot | 24 |
lymphocyte count | 24 |
early treatment | 24 |
reduce mortality | 24 |
herpes simplex | 24 |
treat covid | 24 |
therapeutic effects | 24 |
teniendo en | 24 |
insurance coverage | 24 |
also common | 24 |
granulation tissue | 24 |
ct colonography | 24 |
hypersensitivity reactions | 24 |
en caso | 24 |
molecular mimicry | 24 |
therapeutic proteins | 24 |
esophageal obstruction | 24 |
animal medicine | 24 |
may remain | 24 |
abdominal organs | 24 |
therapeutic strategy | 24 |
metastatic disease | 24 |
epithelial cell | 24 |
guided biopsy | 24 |
fda approval | 24 |
ct examinations | 23 |
surgical approach | 23 |
endovascular treatment | 23 |
medical school | 23 |
therapeutic potential | 23 |
intercostal space | 23 |
study aims | 23 |
study conducted | 23 |
acute sinusitis | 23 |
marshfi eld | 23 |
often seen | 23 |
blood agar | 23 |
medical conditions | 23 |
lung parenchyma | 23 |
feeding tubes | 23 |
avium subsp | 23 |
complication rate | 23 |
molecular biology | 23 |
clinical academics | 23 |
health systems | 23 |
several clinical | 23 |
infected individuals | 23 |
recent report | 23 |
significantly associated | 23 |
molecular mechanisms | 23 |
potential clinical | 23 |
blood sample | 23 |
antimicrobial stewardship | 23 |
venous thrombosis | 23 |
experimental study | 23 |
inflammatory responses | 23 |
arterial hypertension | 23 |
streptococcus pneumoniae | 23 |
typical clinical | 23 |
grade iii | 23 |
close contact | 23 |
si el | 23 |
clinical case | 23 |
el personal | 23 |
patients died | 23 |
decision support | 23 |
skin scrapings | 23 |
hepatic insufficiency | 23 |
tumour size | 23 |
serum alp | 23 |
increased liver | 23 |
pg ml | 23 |
ethics committees | 23 |
hepatic lesions | 23 |
fluid volume | 23 |
colonic mucosa | 23 |
mouth disease | 23 |
bone tumours | 23 |
treatment duration | 23 |
chest radiographs | 23 |
tight junctions | 23 |
mineral oil | 23 |
cause disease | 23 |
lung diseases | 23 |
type iii | 23 |
inflammatory reaction | 23 |
anaerobic bacteria | 23 |
nerve palsy | 23 |
vitro studies | 23 |
will describe | 23 |
highly variable | 23 |
develop severe | 23 |
tested positive | 23 |
serum biochemical | 23 |
adverse effect | 23 |
beneficial effect | 23 |
venous blood | 23 |
many different | 23 |
postoperative complications | 23 |
milk replacers | 23 |
el tiempo | 23 |
hair coat | 23 |
hepatic function | 23 |
liver fibrosis | 23 |
histopathologic examination | 23 |
include anorexia | 23 |
copper toxicosis | 23 |
therapeutic drug | 23 |
intramedullary nailing | 23 |
abdominal palpation | 23 |
pain management | 23 |
obstructive pulmonary | 23 |
transmission occurs | 23 |
severe stage | 23 |
angiotensin receptor | 23 |
anterior chamber | 23 |
serum chemistry | 23 |
calcium phosphate | 23 |
angiotensin converting | 23 |
control groups | 23 |
symptomatic treatment | 23 |
healthcare systems | 23 |
corpus callosum | 23 |
cardiac arrhythmias | 23 |
early childhood | 23 |
times daily | 23 |
alternative medicine | 23 |
year follow | 23 |
anion gap | 23 |
black disease | 23 |
cause acute | 23 |
inclusion bodies | 23 |
relatively low | 23 |
provide additional | 23 |
hospital death | 22 |
abdominal discomfort | 22 |
four cases | 22 |
room air | 22 |
two major | 22 |
potential complications | 22 |
contrast material | 22 |
affected tissues | 22 |
potomac horse | 22 |
proliferative enteropathy | 22 |
rectal palpation | 22 |
liver lesions | 22 |
daily practice | 22 |
acral lick | 22 |
days postinfection | 22 |
nucleic acids | 22 |
ill patient | 22 |
increasing number | 22 |
structural proteins | 22 |
liver transplant | 22 |
hemolytic streptococci | 22 |
beta toxin | 22 |
wuhan clinical | 22 |
best practice | 22 |
bcg vaccination | 22 |
cystic lesions | 22 |
abdominal effusion | 22 |
rapid detection | 22 |
multiple myeloma | 22 |
imaging manifestations | 22 |
pancreatic duct | 22 |
injury may | 22 |
es una | 22 |
developing countries | 22 |
horse fever | 22 |
strangulating obstruction | 22 |
extracorporeal membrane | 22 |
contrast medium | 22 |
may detect | 22 |
cranial nerves | 22 |
systemic hypertension | 22 |
copper concentrations | 22 |
bone defects | 22 |
advanced imaging | 22 |
among children | 22 |
autologous bone | 22 |
cell proliferation | 22 |
france please | 22 |
serious adverse | 22 |
patient may | 22 |
side effect | 22 |
long periods | 22 |
increased vascular | 22 |
bone grafts | 22 |
urethral obstruction | 22 |
without clinical | 22 |
consentimiento informado | 22 |
currently used | 22 |
rectal cancer | 22 |
disease associated | 22 |
radiographic findings | 22 |
adaptive immune | 22 |
crystalloid fluid | 22 |
common findings | 22 |
selected patients | 22 |
term follow | 22 |
bacillus anthracis | 22 |
clinical questions | 22 |
del estado | 22 |
quality assessment | 22 |
economic impact | 22 |
enhanced ct | 22 |
significantly improved | 22 |
infection rate | 22 |
clinical suspicion | 22 |
kg im | 22 |
information provided | 22 |
contaminated feed | 22 |
renal perfusion | 22 |
important factor | 22 |
musculoskeletal system | 22 |
tissue cysts | 22 |
aseptically scrub | 22 |
one also | 22 |
large volumes | 22 |
bone defect | 22 |
acid secretion | 22 |
total protein | 22 |
personal communication | 22 |
current clinical | 22 |
higher levels | 22 |
infectious causes | 22 |
contrast media | 22 |
one week | 22 |
extremely rare | 22 |
panel discussion | 22 |
contagious ecthyma | 22 |
younger animals | 22 |
immunocompromised patients | 22 |
emission tomography | 22 |
brain tissue | 22 |
iv fluids | 22 |
positron emission | 22 |
health record | 22 |
become available | 22 |
genome sequence | 22 |
virus replication | 22 |
fatty liver | 22 |
respiratory pathogens | 22 |
gastric ph | 22 |
may note | 22 |
life threatening | 22 |
pathologic changes | 22 |
serological tests | 22 |
require surgical | 22 |
used successfully | 22 |
hepatic diseases | 22 |
conducted using | 22 |
human cases | 22 |
goat kids | 22 |
study also | 22 |
provide information | 22 |
trauma surgery | 22 |
syndrome differentiation | 22 |
ventricular dysrhythmias | 22 |
use authorization | 22 |
disease will | 22 |
radiofrequency ablation | 22 |
available evidence | 22 |
carrier animals | 22 |
medical students | 22 |
mri will | 22 |
limited number | 22 |
ct perfusion | 21 |
patient information | 21 |
elevated liver | 21 |
disease outbreaks | 21 |
techniques will | 21 |
drug information | 21 |
extremely important | 21 |
glucose levels | 21 |
baseline characteristics | 21 |
late gestation | 21 |
severe sepsis | 21 |
free water | 21 |
metabolic disorders | 21 |
macrophage activation | 21 |
time period | 21 |
also result | 21 |
specific antibodies | 21 |
three different | 21 |
heartworm disease | 21 |
pattern recognition | 21 |
severe hepatic | 21 |
coronary arteries | 21 |
small amount | 21 |
glass opacity | 21 |
fatty acid | 21 |
chronic progressive | 21 |
care setting | 21 |
hip dysplasia | 21 |
chronic hepatic | 21 |
classified according | 21 |
los casos | 21 |
delayed diagnosis | 21 |
selected cases | 21 |
ventral colon | 21 |
ang ii | 21 |
definitive treatment | 21 |
infectious agent | 21 |
led trials | 21 |
improvement criteria | 21 |
recombinant human | 21 |
portosystemic shunt | 21 |
enteral feeding | 21 |
thromboembolic disease | 21 |
wound closure | 21 |
one third | 21 |
intravascular hemolysis | 21 |
liver metastases | 21 |
postoperative period | 21 |
examination may | 21 |
case study | 21 |
relatively high | 21 |
studies using | 21 |
national institutes | 21 |
low molecular | 21 |
may represent | 21 |
influenza viruses | 21 |
american society | 21 |
sudden onset | 21 |
chlamydia psittaci | 21 |
ace receptor | 21 |
cns excitation | 21 |
surgical procedure | 21 |
highly pathogenic | 21 |
massive transfusion | 21 |
invasive ventilation | 21 |
may decrease | 21 |
inflammatory process | 21 |
ml syringe | 21 |
vary depending | 21 |
falla respiratoria | 21 |
frequently observed | 21 |
biochemical abnormalities | 21 |
various types | 21 |
lung base | 21 |
related complications | 21 |
ammonia concentration | 21 |
clinical picture | 21 |
nursing homes | 21 |
broad range | 21 |
young people | 21 |
digestive tract | 21 |
pregnant patients | 21 |
peritoneal lavage | 21 |
mild disease | 21 |
sars outbreak | 21 |
particularly useful | 21 |
factors may | 21 |
human body | 21 |
necrotizing enterocolitis | 21 |
interval prolongation | 21 |
intellectual disability | 21 |
normal flora | 21 |
cardiovascular risk | 21 |
bovine rhinotracheitis | 21 |
assessed using | 21 |
reproductive tract | 21 |
within months | 21 |
neonatal intensive | 21 |
may contain | 21 |
hand hygiene | 21 |
multiple clinical | 21 |
common symptoms | 21 |
significant reduction | 21 |
wound therapy | 21 |
based medicine | 21 |
moderate covid | 21 |
cardiogenic shock | 21 |
para pacientes | 21 |
two main | 21 |
venous thromboembolism | 21 |
control seizures | 21 |
para los | 21 |
may exhibit | 21 |
virus entry | 21 |
cell tumor | 21 |
line treatment | 21 |
none declared | 21 |
postoperative ileus | 21 |
may aid | 21 |
infectious complications | 21 |
restricted diffusion | 21 |
regenerative medicine | 21 |
clinical condition | 21 |
liver cancer | 21 |
congenital defects | 21 |
lower limb | 21 |
final diagnosis | 21 |
head tilt | 21 |
plain radiographs | 21 |
activity may | 21 |
van hoosier | 21 |
scientific community | 21 |
fluid accumulation | 21 |
prone position | 21 |
mouse models | 21 |
antibody responses | 21 |
response criteria | 21 |
multiorgan failure | 21 |
severe trauma | 21 |
respiratory function | 21 |
care team | 21 |
common diseases | 21 |
invasive procedures | 21 |
treatment plan | 21 |
high frequency | 21 |
splenic injury | 21 |
mucosal ulceration | 21 |
vesicular stomatitis | 21 |
wall thickness | 21 |
effective dose | 21 |
rapid diagnosis | 21 |
pathogenic bacteria | 21 |
tocilizumab treatment | 21 |
allergic rhinitis | 20 |
specific diagnosis | 20 |
histologic examination | 20 |
helicobacter mustelae | 20 |
bile salts | 20 |
may reflect | 20 |
acute myocardial | 20 |
asymptomatic carriers | 20 |
human monoclonal | 20 |
acetabular fractures | 20 |
independent risk | 20 |
primary disease | 20 |
data quality | 20 |
tritrichomonas foetus | 20 |
oral anticoagulants | 20 |
hospitalized covid | 20 |
ductus arteriosus | 20 |
day group | 20 |
receptor binding | 20 |
will illustrate | 20 |
much less | 20 |
nine patients | 20 |
progressive disease | 20 |
high degree | 20 |
large volume | 20 |
transmission dynamics | 20 |
room temperature | 20 |
articular surface | 20 |
multicenter cohort | 20 |
regional lymph | 20 |
acute stroke | 20 |
key point | 20 |
zinc sulfate | 20 |
gram stain | 20 |
treatment guidelines | 20 |
protective effect | 20 |
identify patients | 20 |
host disease | 20 |
antigen detection | 20 |
study aimed | 20 |
toxicity include | 20 |
neutrophilic leukocytosis | 20 |
recently emerged | 20 |
para evitar | 20 |
must also | 20 |
current knowledge | 20 |
based approach | 20 |
deceased patients | 20 |
bone grafting | 20 |
pcr test | 20 |
educational exhibit | 20 |
tratamiento con | 20 |
estos pacientes | 20 |
epidemiologic features | 20 |
fracture healing | 20 |
en china | 20 |
patients affected | 20 |
bovine viral | 20 |
small molecule | 20 |
newborn foals | 20 |
almost always | 20 |
orthopaedic surgery | 20 |
thoracic trauma | 20 |
diffusion tensor | 20 |
infected cells | 20 |
preliminary data | 20 |
blood transfusions | 20 |
studies showed | 20 |
es el | 20 |
per minute | 20 |
natural infections | 20 |
infected cats | 20 |
microscopic examination | 20 |
imaging appearances | 20 |
watery diarrhea | 20 |
rhesus monkeys | 20 |
pelvic pain | 20 |
clinical failure | 20 |
brain tumours | 20 |
specific antibody | 20 |
monkeypox virus | 20 |
several times | 20 |
interquartile range | 20 |
data extraction | 20 |
hospital setting | 20 |
recently published | 20 |
functional information | 20 |
center experience | 20 |
although many | 20 |
healthy controls | 20 |
still unclear | 20 |
active disease | 20 |
es importante | 20 |
modified live | 20 |
controlled study | 20 |
severe head | 20 |
salmonella typhimurium | 20 |
older cats | 20 |
treatment strategy | 20 |
ultrasonographic findings | 20 |
older people | 20 |
health records | 20 |
active ingredient | 20 |
nasal swabs | 20 |
pandemic influenza | 20 |
general practitioner | 20 |
take place | 20 |
dendritic cells | 20 |
organisms may | 20 |
meq kg | 20 |
standard deviation | 20 |
hyperactivity disorder | 20 |
natural killer | 20 |
endothelial dysfunction | 20 |
host response | 20 |
care system | 20 |
inflammatory syndrome | 20 |
data will | 20 |
vice versa | 20 |
nasal cannula | 20 |
dental coverage | 20 |
gastrointestinal diseases | 20 |
head injury | 20 |
acute abdomen | 20 |
adult worms | 20 |
initial diagnosis | 20 |
magnesium sulfate | 20 |
malignant tumors | 20 |
acute disease | 20 |
skull base | 20 |
patient populations | 20 |
severe inflammation | 20 |
specific gravity | 20 |
data available | 20 |
breed dogs | 20 |
serum biochemistry | 20 |
respiratory diseases | 20 |
glass opacities | 20 |
protective effects | 20 |
nonhuman primate | 20 |
medication reviews | 20 |
wild animals | 20 |
cell transplantation | 20 |
tissue necrosis | 20 |
mass lesions | 20 |
antiretroviral therapy | 20 |
hepatic enzyme | 20 |
months old | 20 |
young horses | 20 |
botulinum toxin | 20 |
diseases may | 20 |
may demonstrate | 20 |
cerebral blood | 20 |
first days | 20 |
cells may | 19 |
artificial insemination | 19 |
effectively inhibit | 19 |
pulmonary arteries | 19 |
general hospital | 19 |
sars cov | 19 |
neutralizing antibody | 19 |
coronavirus spike | 19 |
confidence intervals | 19 |
american academy | 19 |
vital signs | 19 |
antiviral treatment | 19 |
body wall | 19 |
serum levels | 19 |
exocrine pancreatic | 19 |
cual se | 19 |
clinical education | 19 |
study highlights | 19 |
virus type | 19 |
systemic antibiotics | 19 |
pleural space | 19 |
induced lung | 19 |
stasis syndrome | 19 |
gastroprotectant drugs | 19 |
cheek teeth | 19 |
also lead | 19 |
found dead | 19 |
ct examination | 19 |
lo tanto | 19 |
physical distancing | 19 |
confidence interval | 19 |
low level | 19 |
patient underwent | 19 |
trauma centers | 19 |
patient selection | 19 |
cardiac failure | 19 |
precision medicine | 19 |
time clinical | 19 |
fluid resuscitation | 19 |
fluid analysis | 19 |
brain tumour | 19 |
fi rst | 19 |
classification system | 19 |
patients required | 19 |
normal variants | 19 |
laboratory setting | 19 |
marketing authorization | 19 |
kg every | 19 |
foot rot | 19 |
study protocol | 19 |
serum potassium | 19 |
chronic respiratory | 19 |
lateral recumbency | 19 |
significant role | 19 |
specific therapy | 19 |
acupuncture treatment | 19 |
abnormalities may | 19 |
activation syndrome | 19 |
affected individuals | 19 |
traumatic injuries | 19 |
vaccination programs | 19 |
mean arterial | 19 |
saudi arabia | 19 |
chronic renal | 19 |
injection site | 19 |
oral mucosa | 19 |
epidemiological characteristics | 19 |
sequence analysis | 19 |
large quantities | 19 |
jia patients | 19 |
medication discrepancies | 19 |
bowel wall | 19 |
good prognosis | 19 |
treat supportively | 19 |
penetrating trauma | 19 |
molecular methods | 19 |
less toxic | 19 |
care costs | 19 |
acute pharyngo | 19 |
new techniques | 19 |
neonatal foal | 19 |
signal quality | 19 |
term use | 19 |
nasal cavity | 19 |
like receptors | 19 |
ultrasound guidance | 19 |
disease clinical | 19 |
severe forms | 19 |
mucosal blood | 19 |
term prognosis | 19 |
factor viii | 19 |
plain radiography | 19 |
abdominal injuries | 19 |
tissue contrast | 19 |
hasta el | 19 |
cell carcinomas | 19 |
regulatory authorities | 19 |
also play | 19 |
melopsittacus undulatus | 19 |
human genome | 19 |
adult animals | 19 |
mortality due | 19 |
south africa | 19 |
also associated | 19 |
intracranial pressure | 19 |
serum lactate | 19 |
laboratory data | 19 |
least months | 19 |
cancer screening | 19 |
primate model | 19 |
novel therapeutic | 19 |
pulmonary vascular | 19 |
current study | 19 |
person transmission | 19 |
old man | 19 |
los cuales | 19 |
spinal fusion | 19 |
also include | 19 |
clinical translation | 19 |
thyroid hormone | 19 |
vitro antiviral | 19 |
dental disease | 19 |
nonsteroidal anti | 19 |
limited data | 19 |
medical research | 19 |
salivary glands | 19 |
streptobacillus moniliformis | 19 |
clinical medicine | 19 |
tract obstruction | 19 |
fecal culture | 19 |
corneal ulcers | 19 |
entre los | 19 |
commonly encountered | 19 |
first cases | 19 |
therapeutic target | 19 |
urgent need | 19 |
pulmonary function | 19 |
several years | 19 |
clinical severity | 19 |
infective larvae | 19 |
intravenously every | 19 |
una serie | 19 |